WATCH LIVE
timothy sykes logo
Kymera Therapeutics KYMR Stock Surges On Sanofi Milestone Thumbnail
G Google News

Kymera Therapeutics KYMR Stock Surges On Sanofi Milestone

MATT MONACO•UPDATED JUN. 25, 2026, 2:33 PM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Kymera Therapeutics Inc. stocks have been trading up by 16.94 percent following highly positive news on its drug development progress.

Key Takeaways

  • Sanofi milestone payment of $20M to Kymera follows first dosing in the KT-485 Phase 1 trial, within a partnership that may deliver up to $975M in milestones plus profit-share and royalties.
  • Phase 1 KT-621 data in healthy Japanese adults confirm strong STAT6 degradation and safety, keeping global Phase 2b atopic dermatitis and asthma trials on track for 2027 readouts.
  • New KT-579 lupus preclinical results show disease-modifying activity at or above approved therapies, backing an ongoing Phase 1 trial with data expected in 2H26.
  • Kymera elevated biotech heavyweight Felix J. Baker to Chairman as co-founder Bruce Booth shifts to independent director, signaling a new governance phase.
  • Director Booth sold Kymera shares worth about $45.3M on 2026/06/17 yet still indirectly controls roughly 4.1M shares, keeping sizable skin in the game.

Candlestick Chart

Live Update At 14:32:49 EDT: On Thursday, June 25, 2026 Kymera Therapeutics Inc. stock [NASDAQ: KYMR] is trending up by 16.94%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

KYMR has been on a sharp upswing. In early June, Kymera Therapeutics shares closed around $71–75. By 2026/06/25, KYMR finished at $116.79 after touching an intraday high of $130.05. That is a powerful multi-week trend, with the stock climbing more than 50% from early-month lows.

Intraday action tells the same story. KYMR opened at $108.80 and ripped into the $120s within the first hour, then spent the day consolidating between about $116 and $121. That kind of gap-and-hold pattern often reflects strong demand, with dip buyers stepping in on each pullback.

Fundamentals show why traders treat Kymera like a high-beta biotech momentum play. Revenue in the latest quarter was only about $34.4M, and the company posted a net loss of roughly $69.2M, with EBITDA at about -$67.2M. Key profitability ratios for KYMR are deep in the red, and the price-to-sales multiple is a lofty 129.55.

More Breaking News

But Kymera Therapeutics also holds about $650.9M in cash and short-term investments, very low debt, and a current ratio above 10. For traders, that mix—big losses, big cash, and a strong chart—screams “clinical and news-driven story,” not value play.

Why Traders Are Watching KYMR

What is driving KYMR through the $100 level is not earnings; it is pipeline and partnerships. Kymera Therapeutics just hit a big operational and financial milestone with partner Sanofi. First dosing in the Phase 1 trial of KT-485, a second-generation oral IRAK4 degrader for hidradenitis suppurativa, triggered a $20M cash milestone. The Sanofi collaboration carries up to $975M in potential milestones plus U.S. profit-share and ex-U.S. royalties. For traders, this is both validation and non-dilutive funding that stretches Kymera’s runway.

At the same time, KYMR is building a clearer clinical roadmap. For KT-621, its first-in-class oral STAT6 degrader, Phase 1 data in healthy Japanese adults mirrored earlier non-Japanese and atopic dermatitis work. Pharmacokinetics and pharmacodynamics lined up, safety was solid, and Kymera saw ≥98% STAT6 degradation. That consistency gives traders a defined catalyst: global Phase 2b trials in atopic dermatitis and asthma, with readouts targeted for 2027.

Pipeline depth adds another angle. Kymera Therapeutics reported new preclinical data for KT-579, an oral IRF5 degrader for lupus, showing disease-modifying activity in multiple models, with biomarker drops comparable or superior to approved or clinically active therapies. A Phase 1 healthy volunteer study is already underway, with data expected in 2H26 and plans for a subsequent patient proof-of-concept trial, likely in lupus. Those 2H26 and 2027 windows give KYMR a clear catalyst ladder.

On top of that, the boardroom is shifting. Kymera Therapeutics named Felix J. Baker, a well-known biotech specialist, as Chairman, with co-founder Bruce Booth staying on as an independent director. Traders often see Baker’s presence as a signal of deep due diligence and long-term conviction.

Insider activity is the one caution flag. Booth sold hundreds of thousands of KYMR shares on 2026/06/17 for roughly $45.3M, plus another sale around $3.3M, yet still controls about 4.1M shares indirectly. For active traders, that looks more like partial profit-taking during strength than an exit.

Conclusion

Put it together and KYMR is trading like a textbook biotech momentum setup. Kymera Therapeutics has a rich cash pile, a suite of oral degrader programs in immunology, and a heavyweight partner in Sanofi backing KT-485 with real money—$20M already in the door and up to $975M on the table. KT-621 STAT6 data in Japan de-risk global Phase 2b plans, while KT-579’s lupus data suggest meaningful upside if human studies echo the preclinical profile.

The leadership story adds fuel. With Felix Baker stepping in as Chairman and Penny Carlson taking over Development Operations as the company scales global trials, KYMR is positioning its bench for the next phase. Insider selling by Bruce Booth is a reality traders must respect, but his remaining multi-million-share stake shows he has not walked away from Kymera’s future.

For short-term traders, KYMR’s recent run from the $70s into triple digits, plus tight intraday consolidations, demands strict risk management and clear trading plans. For those studying the name, the real lesson is how news, catalysts, and liquidity line up. As millionaire penny stock trader and teacher Tim Sykes, says, “Cut losses quickly, let profits ride, and don’t overtrade.” That mindset ties directly into how disciplined traders should approach this kind of high-volatility biotech mover. As Tim Sykes likes to say, “Patterns repeat because human nature doesn’t change—your job is to recognize them and manage risk like a pro.” Kymera Therapeutics is offering that pattern in real time, and traders are watching every headline.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”